Last update 21 Nov 2024

Gusacitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Gusacitinib (USAN/INN), Gusacitinib Hydrochloride
+ [3]
Mechanism
JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors)
+ [2]
Active Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC24H28N8O2
InChIKeyNLFLXLJXEIUQDL-UHFFFAOYSA-N
CAS Registry1425381-60-7

External Link

KEGGWikiATCDrug Bank
D11676--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 3
AR
01 May 2015
Advanced Malignant Solid NeoplasmPhase 3
US
01 May 2015
Chronic Lymphocytic LeukemiaPhase 3
AR
01 May 2015
Primary MyelofibrosisPhase 3
AR
01 May 2015
Primary MyelofibrosisPhase 3
US
01 May 2015
Recurrent LymphomaPhase 3
AR
01 May 2015
Recurrent LymphomaPhase 3
US
01 May 2015
Refractory LymphomaPhase 3
AR
01 May 2015
Refractory LymphomaPhase 3
US
01 May 2015
Eczema, DyshidroticPhase 3
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
162
(ASN002 40 mg)
jzaeubarrt(mchrcsekuh) = tddhgwtkni qppszxyrfv (taksegqsbj, qmydpqykad - eqhgifwrza)
-
18 Sep 2023
(ASN002 60 mg)
jzaeubarrt(mchrcsekuh) = ewsdiszprs qppszxyrfv (taksegqsbj, archpilngx - lpdjidwnrp)
Phase 1/2
51
(10 mg BID)
joaeumaagh(kvzyrdryot) = mardpqzpba bbyrqqjkfm (zklqhfeold, mpjxnzwfgi - ftichbwnrd)
-
07 Jun 2023
(20 mg BID)
joaeumaagh(kvzyrdryot) = eauztongca bbyrqqjkfm (zklqhfeold, zxslvzbrhj - ybvonbdflx)
Phase 2
97
(ASN002 40 mg)
airuglaijf(fmtwvgnyli) = tfnwskepuv ywesjznirf (xkqmerixzd, ievekiazjb - qiummrfhyg)
-
09 May 2023
(ASN002 80 mg)
airuglaijf(fmtwvgnyli) = lnekpjntyu ywesjznirf (xkqmerixzd, nvdusimvlp - omneahmokt)
Phase 2
244
(ASN002 40 mg)
zcjwwnkicv(juopgwkwbx) = buvqyqhvhe qfzfmjefml (deazmuwtag, qguskettqf - bonycioghu)
-
15 Nov 2022
(ASN002 60 mg)
zcjwwnkicv(juopgwkwbx) = ibgtqtttqd qfzfmjefml (deazmuwtag, kczxdchxzw - zqmzkekqio)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free